CompletedPhase 1NCT04002687

Determine the Tolerability and Safety of Atovaquone-proguanil (ATV-PG) Co-administered With Amodiaquine (AQ)

Studying Malaria

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Medicines for Malaria Venture
Principal Investigator
Ulrike Lorch, MD FRCA FFPM
Richmond Pharmacology Limited
Intervention
ATV-PG 1000-400 mg + AQ 612 mg(drug)
Enrollment
44 target
Eligibility
18-45 years · All sexes
Timeline
20192019

Study locations (1)

Collaborators

Richmond Pharmacology Limited

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04002687 on ClinicalTrials.gov

Other trials for Malaria

Additional recruiting or active studies for the same condition.

See all trials for Malaria

← Back to all trials